Someone described psychedelic-assisted therapy to me once as ten years of therapy rolled into one session. I understood what they meant. There is something about the experience that can cut through — directly to the material that years of talk therapy might only circle around slowly. Defences that ordinarily take months to soften can dissolve in hours. Connections that felt out of reach suddenly become obvious.
But I want to be honest with you about something right from the start: that description, while not inaccurate, can also be misleading. Because the session itself is not the therapy. The session is the opening. What happens before and after — the preparation and the integration — is where the actual therapeutic work lives. Without that container, a profound experience can be just that: an experience. Interesting, even life-changing in the moment, but not necessarily integrated into lasting change.
I hold a Psychedelic Facilitator Certification through Phoenix Academy, and I want to use this post to give you an honest, careful overview of what this field actually involves — the research, the substances, the legal landscape in Canada, and what responsible practice actually looks like.
Important note before we begin
This post is educational, not a recommendation. Psychedelic-assisted therapy is not appropriate for everyone, and in many cases the substances involved are still controlled under Canadian law. Nothing here should be taken as encouragement to use psychedelics outside of a legal, supervised therapeutic context. If you are considering this path, please do so with proper professional guidance.
What is psychedelic-assisted therapy?
Psychedelic-assisted therapy is a clinical approach in which a psychedelic substance is used — under careful supervision, within a structured therapeutic framework — to support mental health treatment. It is not recreational use. It is not taking a substance and hoping for the best. It is a highly intentional, medically and therapeutically supervised process with defined protocols for preparation, the session itself, and integration afterwards.
The substances most commonly researched and used in therapeutic contexts include:
Psilocybin
Access via SAP in Canada
The active compound in psychedelic mushrooms. Most extensively researched for depression, end-of-life anxiety, and addiction. Studies from Johns Hopkins and Imperial College London have shown significant promise.
MDMA
Phase 3 trials ongoing
Most researched for PTSD. MAPS (Multidisciplinary Association for Psychedelic Studies) has led clinical trials showing significant reductions in PTSD symptoms, often in people for whom other treatments had failed.
Ketamine
Legal in Canada
An anaesthetic with dissociative properties, ketamine is currently the only psychedelic-adjacent substance that is fully legal for therapeutic use in Canada. Used for treatment-resistant depression, anxiety, and PTSD. Can be administered in clinical settings by licensed practitioners.
Ayahuasca
Legal grey area
A plant medicine with deep roots in Indigenous Amazonian traditions. Used in ceremonial contexts, some of which operate legally in Canada. Research into therapeutic applications is ongoing, though the regulatory landscape is complex.
Is it legal in Canada?
The short answer is: it depends on the substance and the context.
Ketamine is fully legal in Canada and can be prescribed and administered by licensed medical practitioners. Ketamine-assisted therapy clinics exist in several Canadian cities, including Vancouver.
Psilocybin remains a controlled substance in Canada, but access is possible through Health Canada's Special Access Program (SAP), which allows patients with serious or life-threatening conditions to access restricted substances when conventional treatments have been insufficient. A growing number of practitioners are obtaining SAP approvals for psilocybin-assisted therapy in Canada.
MDMA is also a controlled substance and not yet approved for therapeutic use in Canada, though clinical trials are ongoing through MAPS and other organisations. The regulatory landscape is evolving quickly.
For the most current information on legal access in Canada, Health Canada's psychedelics page is the most reliable source.
The three pillars — preparation, session, integration
This is the part that gets left out of most conversations about psychedelic therapy — and it is the most important part.
Preparation
Sessions of work with a trained therapist before the psychedelic experience. This involves building trust, clarifying intentions, understanding what to expect, working through any contraindications, and establishing safety protocols. This is not a formality — it is the foundation on which everything else rests. Skipping or rushing preparation is one of the most common mistakes in poorly conducted psychedelic work.
The session
The psychedelic experience itself, conducted in a carefully prepared setting with a trained guide or therapist present. The role of the guide is not to direct the experience but to hold a safe, grounded container — so that whatever arises can be met with support rather than fear. Music, eyeshades, and a reclining position are common elements of structured sessions.
Integration
The work that happens after. This is where the experience gets processed, understood, and woven into daily life. Many people find that the insights from a session are vivid immediately afterwards but begin to fade without deliberate integration work. Therapy, journalling, somatic practices, and community support can all be part of this. Integration is not optional — it is what turns an experience into lasting change.
Who is it not for?
This is as important as anything else in this post. Psychedelic-assisted therapy carries real contraindications and is not appropriate for everyone. People with a personal or family history of psychosis or bipolar disorder with psychotic features are generally not good candidates. Those on certain medications — particularly SSRIs and MAOIs — need careful screening. People in acute crisis, with active suicidality, or with significant cardiovascular conditions also require careful assessment.
Beyond the medical contraindications, timing and readiness matter enormously. A psychedelic experience can open up significant emotional material very quickly. Without adequate support — a skilled guide, a safe container, and a plan for integration — that opening can be destabilising rather than healing. The goal is not to have an intense experience. The goal is sustainable, integrated change.
Responsible practitioners in this field will not rush anyone through screening, and they will be honest when they do not think the timing is right.
The research is genuinely exciting
It is worth saying clearly: this is one of the most promising areas of mental health research in decades. Studies of psilocybin-assisted therapy have shown significant reductions in depression and anxiety, including in people who had not responded to conventional treatments. MDMA-assisted therapy for PTSD has produced results that are, by some measures, more significant than any other intervention currently available. Ketamine has shown rapid-onset antidepressant effects that can be life-saving in acute situations.
This does not mean psychedelic therapy is a cure or that it works for everyone. But it does mean the scientific community is taking it seriously — and so should we.
For those who want to go deeper into the research, the Beckley Foundation and MAPS research library are excellent starting points. In Canada, Numinus is one of the leading organisations doing clinical research and providing legal ketamine-assisted therapy.
A word on where this field is heading
The regulatory landscape around psychedelic-assisted therapy in Canada is moving faster than most people realise. Health Canada has been expanding access through the Special Access Program, and it is likely that we will see more formalised pathways for psilocybin therapy in the coming years. For practitioners training in this area now — as I am — the goal is to be ready to offer this work responsibly and legally when those pathways open further.
If you are curious about psychedelic-assisted therapy and want to explore whether it might be relevant to your situation, the most important step is finding a practitioner who is trained, ethical, and honest about what they can and cannot offer within the current legal framework. Do not be afraid to ask detailed questions about their training, their protocols, and their approach to preparation and integration.
My practice opens in Vancouver in January 2027. Psychedelic integration therapy — supporting people before and after psychedelic experiences — will be part of my clinical offering. Join the list to be notified when I am accepting clients.
Hilary McKee is an emerging psychotherapist completing her MA in Counselling Psychology at Yorkville University, a Certified Psychedelic Facilitator (Phoenix Academy), and the Co-Founder and CEO of P.A.T.H. Therapy. She writes about therapy, the nervous system, and the work of healing. Her practice opens in Vancouver in January 2027, offering in-person and virtual sessions across British Columbia and Canada. The content of this post is educational only and does not constitute medical or therapeutic advice.